CSL is in very good financial health and is able to fund all its capital and R&D spending, a combined 20% of revenues, as well as maintain a dividend payout ratio of 45% without requiring much ...

CSL is in good financial health and can fund all its capital and R&D spending, currently a combined 18% of revenue, as well as maintain a dividend payout ratio of 44% without requiring additional ...

By contrast, CSL’s plasma arm – CSL Behring – emerged as key to current support for the company and its outlook. Immunoglobulin sales remain strong, with reported double-digit growth and ...

Overall net profit rose 6% to $2.01 billion, driven by a 10% rise in revenue from CSL's main blood-plasma business Behring. But the profit was slightly below analysts' forecasts of $2.09 billion.

But don’t worry too much, CSL shareholders. Not for the first time, CSL’s core Behring plasma arm has come to the rescue with a rock-solid performance, led by its immunoglobulin products.

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL ...